KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill & Intangibles (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Goodwill & Intangibles for 3 consecutive years, with $818.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Goodwill & Intangibles rose 73.12% to $818.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $818.7 million, a 73.12% increase, with the full-year FY2024 number at $818.7 million, up 73.12% from a year prior.
  • Goodwill & Intangibles was $818.7 million for Q4 2024 at Halozyme Therapeutics, up from $472.9 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $818.7 million in Q4 2024 to a low of $472.9 million in Q4 2023.
  • A 3-year average of $612.7 million and a median of $546.7 million in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: fell 13.5% in 2023, then soared 73.12% in 2024.
  • Halozyme Therapeutics' Goodwill & Intangibles stood at $546.7 million in 2022, then dropped by 13.5% to $472.9 million in 2023, then skyrocketed by 73.12% to $818.7 million in 2024.
  • Per Business Quant, the three most recent readings for HALO's Goodwill & Intangibles are $818.7 million (Q4 2024), $472.9 million (Q4 2023), and $546.7 million (Q4 2022).